Proniras
Seattle
About Proniras
Proniras Corp is an operator of a biomedical company intended to develop drugs. The company's biomedical service has already demonstrated preclinical efficacy in treating nerve agent-induced seizures, as well as in studies of rodents exposed to the chemical weapon soman, which is more toxic than sarin gas, enabling medical researchers to continue their research work and discover drugs. It was founded in 2016 and is headquartered in Seattle, Washington.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $8.9M
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2024)
- Website: proniras.com
- Phone: 206-957-7300
Industries & Categories
Biotechnology, Health Care, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/proniras-53620 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.